MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 24 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $42,686,046 | +27.3% | 748,878 | +13.9% | 0.00% | 0.0% |
Q2 2023 | $33,534,234 | +1264.1% | 657,534 | +472.1% | 0.00% | – |
Q1 2023 | $2,458,353 | -68.4% | 114,930 | -84.5% | 0.00% | – |
Q4 2022 | $7,788,461 | +35.3% | 741,758 | -0.0% | 0.00% | – |
Q3 2022 | $5,756,000 | +47.8% | 741,832 | -0.0% | 0.00% | – |
Q2 2022 | $3,895,000 | – | 741,906 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 21,751,284 | $1,239,823,188 | 33.43% |
Cormorant Asset Management, LP | 8,142,100 | $464,099,700 | 27.07% |
Ally Bridge Group (NY) LLC | 183,105 | $10,436,985 | 12.25% |
Finepoint Capital LP | 331,416 | $18,890,712 | 9.41% |
Ghost Tree Capital, LLC | 330,000 | $18,810,000 | 6.19% |
5AM Venture Management, LLC | 313,210 | $17,852,970 | 5.14% |
Ghost Tree Capital, LLC | 250,000 | $14,250,000 | 4.69% |
MPM BioImpact LLC | 294,190 | $16,768,830 | 4.48% |
Integral Health Asset Management, LLC | 500,000 | $28,500,000 | 3.95% |
Altium Capital Management LP | 88,000 | $5,016,000 | 2.62% |